Research concerning cannabis, endocannabinoids and Schizophrenia and other psychotic disorders are contained in this section. Recent research has revealed the balance-maintaining purpose of the body’s cannabinoid system plays a major role in Schizophrenia. Some research has revealed that certain cannabinoids, like THC, can cause psychotic episodes, while others — like CBD — can prevent or lessen the symptoms of schizophrenia.
Schizophrenia is a mental disorder where the subject displays abnormal social behavior and an inability to understand and interpret reality the same way as the rest of a population. Symptoms can include hearing voices that others do not, unclear or confused thinking, false beliefs and a lack of motivation. Distortions of self-experience such as a person believing their own thoughts are being inserted by an outside actor.
The research to date shows that reduced expression of the receptors for cannabinoids (as well as the enzymes that create endocannabinoids) has been seen in schizophrenic patients. Research also indicates that CBD is currently one of the most promising cannabinoids for treatment of schizophrenia. Researchers theorize that too little anandamide, a chemical produced by the body’s endocannabinoid system, may be a major cause of schizophrenia. Cannabinoids from cannabis are one of the easiest ways to supplement or alter the balance of anandamide in the body.
Website & branding by the Ganjapreneur in-house agency:
Uplifted cannabis industry branding & marketing.